证券日报网讯 2月11日，东南网架发布公告称，截至本公告披露日，董事会审议批准的有效对外担保额 度累计金额为853500万元人民币，实际发生的担保余额为163081.48万元，占本公司2024年末经审计净 资产的25.09%，均为对本公司全资子公司或控股子公司的担保；公司及控股子公司未对合并报表范围 外的单位提供担保，也无逾期担保累计金额、涉及诉讼的担保金额及因担保被判决败诉而应承担的损失 金额。 （编辑 丛可心） ...

（编辑 丛可心） 证券日报网讯 2月11日，万朗磁塑发布公告称，公司股票于2026年2月9日、2月10日、2月11日连续3个 交易日内日收盘价格涨幅偏离值累计超过20%。根据《上海证券交易所交易规则》的有关规定，属于股 票交易异常波动情形。经公司自查并向控股股东及实际控制人核实，截至本公告披露日，不存在应披露 而未披露的重大信息。 ...

Core Insights - In the first two months of 2026, Yuewen's short dramas have achieved remarkable success, with both male and female genres producing hit works, indicating strong growth potential for the company in the short drama sector [1][3] Group 1: Performance of Short Dramas - The male short drama "Jipin Jiadin" reached a platform popularity of over 53 million, ranking in the top 5 of the hot broadcast list [1] - The female short drama "Nancheng Duiyue Gui" achieved a first-day popularity of 71.5 million and over 100 million views on Douyin within 36 hours, setting a benchmark for female short dramas [1] - Multiple works launched at the beginning of the year have exceeded 50 million in popularity, earning the platform's "explosive drama" certification [2] Group 2: IP and Content Development - Yuewen has a vast reserve of over 10 million premium IPs across various genres, providing a continuous source of story material for short drama creation [2] - The company has established long-term collaborations with top production companies and developed its own short drama production team, enhancing production quality [2] - The successful adaptation of classic web novels into short dramas has solidified the narrative foundation for these adaptations, ensuring sustainability in IP short drama development [2] Group 3: Future Outlook - Yuewen is set to release numerous high-quality IP adaptations in 2026, including "Xu Ni Wan Zhang Guang Mang Hao," "Wo Zhen Mei Xiang Chong Sheng A 2," and "Zhong Song 2" [3] - The company aims to continue deepening its focus on the short drama sector, leveraging its mature methodologies and rich IP reserves to deliver high-quality content [3]

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiaries participated in the national procurement bidding for expiring products, with seven products, including Cefotaxime Sodium Injection, expected to be selected, which could significantly impact the company's revenue [1] Group 1: Company Announcement - Jincheng Pharmaceutical's subsidiary, Jincheng Jinsu, and its wholly-owned subsidiary, Jincheng Suzhi, are participating in the national procurement bidding for products whose agreements are expiring [1] - The seven products expected to be selected are projected to generate sales of 414 million yuan before the third quarter of 2025, accounting for 21.45% of the company's revenue [1] - The results of the selection are anticipated to be finalized by the end of March 2026, with the procurement cycle lasting until December 31, 2028 [1]

（编辑 丛可心） 证券日报网讯 2月11日，利和兴发布公告称，公司控股股东一致行动人黄禹岳及利和兴投资计划自公告 披露15个交易日后3个月内，以集中竞价方式分别减持不超过1060000股、1270824股，各占公司总股本 0.4535%、0.5437%。 ...

（编辑 丛可心） 证券日报网讯 2月11日，今天国际发布公告称，公司股东重庆华锐丰企业管理合伙企业（有限合伙）原 计划在2025年11月20日至2026年2月19日期间减持不超过4533240股（占总股本1%），截至2026年2月11 日未实施减持并决定提前终止减持计划，其持股数量仍为10064864股，占总股本2.22%。 ...

章卫国原本拟通过让渡上市公司控制权，引入实力投资者，借助资金赋能、资源整合等方式推动公司高 质量、可持续发展。目前，骁光智能因自身原因无法继续推进定增相关事宜。本次定增终止及表决权恢 复，是各方本着维护飞鹿股份及全体股东利益的原则作出的决定。 当前，飞鹿股份各项生产经营活动正常开展，公司管理层坚守主业、扎实工作，积极布局新业务，力争 实现新突破。自公司2025年8月份披露控制权变更事项以来，骁光智能及杨奕骁未参与公司实际经营。 本次定增终止与表决权恢复，有助于飞鹿股份在复杂多变的市场环境中稳定核心管理团队与经营战略， 对公司实现可持续发展具有重要意义。公司创始人章卫国也将一如既往地支持公司发展，在战略规划、 管理优化、行业资源整合、企业文化传承等方面持续发挥重要作用。 （编辑 张昕） 本报讯 （记者肖伟）2月11日晚间，株洲飞鹿高新材料技术股份有限公司（以下简称"飞鹿股份"）发布 公告，公司与上海骁光智能技术有限公司（以下简称"骁光智能"）签署《解除协议》，终止向骁光智能 发行股票；公司股东章卫国与骁光智能签署《终止协议》，解除双方于2025年8月25日签订的《表决权 委托协议》。前述协议生效后，章卫国恢复表 ...

（编辑 丛可心） 证券日报网讯 2月11日，盘龙药业发布公告称，公司近日获国家药监局核准签发《药物临床试验批准通 知书》，同意酮洛芬凝胶贴膏开展镇痛临床试验。该化学药品3类规格14cm×10cm含酮洛芬30mg，拟用 于骨关节炎等局部镇痛，目前国内仅湖南九典制药获批上市。 ...

（编辑 丛可心） 证券日报网讯 2月11日，向日葵发布公告称，公司子公司浙江贝得药业有限公司克拉霉素片、辛伐他汀 片拟中选国家组织集采药品协议期满品种接续采购，采购周期至2028年12月31日，2024年两产品合计销 售额3899万元，占公司营收11.81%，若签订购销协议将扩大销售规模。 ...

Group 1 - The company, Helen Zhe, announced that its shareholder, Dinghang Huiheng, pledged 5.2 million shares to CITIC Securities on February 9, 2026, to supplement liquidity, which accounts for 8% of its holdings [1] - On February 10, 2026, Dinghang Huiheng released a pledge of 4 million shares, representing 6.15% of its holdings [1]